Literature DB >> 2722375

Loss of maternal measles antibody during infancy in an African city.

F Dabis1, R J Waldman, G F Mann, D Commenges, G Madzou, T S Jones.   

Abstract

Measles epidemics with 20% of the cases under nine months of age continue to occur in Brazzaville, Congo, even though measles vaccination coverage was 77% in the 12- to 23-month age group in 1986. In order to estimate the duration of passive immunity against measles, we conducted a serologic survey of infants aged 2 to 9 months. Measles antibody was measured from capillary blood with the plaque inhibition test. An antibody titre of 40 milli-International Reference Units per ml of serum (mIRU/ml) or less was defined as seronegative. Among the 252 infants studied, the proportion with detectable antibody dropped from 95.8% at 2 months of age to 48.5% at 4 months of age, and to 8.2% in the 7-8 month age group. A simple logistic model with age as the only variable provided an excellent fit to the observed values. Between the ages of 8 and 28 weeks, there was an almost steady decline of approximately 4.7% per week in the proportion of infants who were seropositive. These findings suggest that loss of maternal measles antibody during infancy might be faster than reported in other African populations. Giving measles vaccine to infants before the age of nine months currently recommended by the Expanded Programme on Immunization may be useful in some populations. Further studies of seroconversion and impact on measles are needed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2722375     DOI: 10.1093/ije/18.1.264

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  8 in total

1.  Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses.

Authors:  C Nicoara; K Zäch; D Trachsel; D Germann; L Matter
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Ideal age for measles vaccination with persisting maternal antibody, human immunodeficiency virus infection and protein-calorie malnutrition.

Authors:  S C Arya
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

Review 3.  Immunization in urban areas: issues and strategies.

Authors:  S J Atkinson; J Cheyne
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

4.  Measles vaccination policy.

Authors:  B G Williams; F T Cutts; C Dye
Journal:  Epidemiol Infect       Date:  1995-12       Impact factor: 2.451

5.  A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.

Authors:  Chien-Hsiung Pan; Catherine E Greer; Debra Hauer; Harold S Legg; Eun-Young Lee; M Jeff Bergen; Brandyn Lau; Robert J Adams; John M Polo; Diane E Griffin
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

6.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

7.  Seroprevalence of measles and natural rubella antibodies among children in Bangui, Central African Republic.

Authors:  Alexandre Manirakiza; Jean Marie Kipela; Stephen Sosler; Régis M'Bary Daba; Ionela Gouandjika-Vasilache
Journal:  BMC Public Health       Date:  2011-05-17       Impact factor: 3.295

8.  A 'post-honeymoon' measles epidemic in Burundi: mathematical model-based analysis and implications for vaccination timing.

Authors:  Katelyn C Corey; Andrew Noymer
Journal:  PeerJ       Date:  2016-09-15       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.